The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...

Lenacapavir is Gilead’s potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection. As an investigational compound, lenacapavir is ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

Lenacapavir has demonstrated enormous potential as a new HIV prevention tool with a 100 per cent efficacy rate and zero ...

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

Nearly 40 million individuals globally are currently living with HIV, a virus that has resulted in the loss of over 42 ...

Lenacapavir was granted breakthrough therapy designation for HIV prevention by the FDA in October 2024 and will be reviewed by the FDA under priority review, with an assigned Prescription Drug User ...

Sunlenca ® (lenacapavir) is a first-in-class capsid inhibitor indicated for the treatment of adults with multi-drug resistant human immunodeficiency virus-1 (HIV-1) infection, for whom the ...

Ehrenkranz sang the praises of lenacapavir as a “really well-tolerated product, incredibly efficacious” that does not require refrigeration. But he also cautioned that “it has to make its way into the ...